-
CStone’s PD-L1 Inhibitor Sugemalimab Accepted for Review in Gastric Cancer
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has accepted for review another market filing for its programmed death-ligand 1 (PD-L1) inhibitor sugemalimab. The filing is for the drug’s use in combination with chemotherapy as a first-line treatment of locally advanced or metastatic gastric/gastroesophageal…
-
Immorna Closes Series A+ and A++ Rounds Near $100M for mRNA Development
•
Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++ financing rounds, raising close to USD 100 million. The funding was led by Guodiao Innovation Private Equity Investment Fund Management (Hainan), Yuexiu Fund, GL Ventures, Zhenji Capital, C&D Emerging Industry Investment, TigerYeah Capital, and others,…
-
Sanofi’s VaxigripTetra Approved for Pediatric Influenza Vaccination in China
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced receiving market approval from the National Medical Products Administration (NMPA) for its VaxigripTetra, a tetravalent influenza virus split vaccine, for use in children aged 6 to 35 months. This approval is significant as children are a primary susceptible population to influenza, with…
-
Enhertu Approved in China for HER2-Positive Breast Cancer
•
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), has been approved by the National Medical Products Administration (NMPA) for the treatment of unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.…
-
Novartis’ Revolade Approved for Severe Aplastic Anemia in China
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its Revolade (eltrombopag olamine tablets). The oral thrombopoietin receptor agonist can now be used to treat severe aplastic anemia (SAA) in patients with inadequate previous remission following immunosuppressive therapy. Revolade:…
-
Kelun-Biotech Files for Hong Kong IPO with Goldman Sachs and CITIC Securities
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its high-end preparation subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, has filed an initial public offering (IPO) with the Hong Kong Stock Exchange. The offering is co-sponsored by Goldman Sachs and CITIC Securities, marking a significant step in the company’s…
-
Accutar Biotech Begins Phase I Trial for AC0176 in China
•
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the first patient dosing in a Phase I trial for AC0176, an orally bioavailable chimeric degrader molecule targeting the androgen receptor protein. This marks a significant milestone in the development of innovative treatments for prostate cancer.…
-
BeiGene’s Tislelizumab Approved for Gastric Tumors in China
•
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor tislelizumab has been approved in China as a first-line therapy for locally advanced unresectable or metastatic gastric/gastroesophageal junction (G/GEJ) tumors where PD-L1 is overexpressed. Specifically, tislelizumab is approved for use in combination with fluorouracil plus…
-
SciClone Partners with Cowell Health to Enhance Cancer Treatment Accessibility
•
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017, has struck a partnership with Cowell Health, Hillhouse Capital’s healthcare-focused wholly-owned subsidiary. The collaboration aims to enhance the accessibility and affordability of high-quality drugs and services, explore a new full-course management model for cancer patients,…
-
Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization
•
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss pharmaceutical giant Novartis (NYSE: NVS) to deepen commercialization operations surrounding Novartis’s Votrient (pazopanib). Votrient is a first-line targeted treatment for advanced kidney cancer, offering significant benefits to patients in need. Votrient: Next-Generation TKIVotrient, a next-generation…
-
Grand Pharma’s First-in-Class RDC ITM-11 Accepted for IND Review
•
China-based Grand Pharmaceutical Group Ltd (HKG: 0512) has announced that an Investigational New Drug (IND) filing for its first-in-class radionuclide drug conjugate (RDC) ITM-11 has been accepted for review. The intended indication for ITM-11 is gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking a significant step forward in the development of novel treatments…
-
Jacobio Pharma Partners with WestChina-Frontier for Preclinical Safety Studies
•
China-based Jacobio Pharma (HKG: 1167) has announced a partnership agreement with compatriot firm WestChina-Frontier PharmaTech, a non-clinical research evaluation organization. The collaboration aims to accelerate pre-clinical safety assessment studies for multiple first-in-class drug candidates. Specifically, the two companies will jointly conduct comprehensive toxicological research on multiple preclinical projects, including the…
-
Mabwell’s IL-11 Monoclonal Antibody 9MW3811 Approved for Australian Clinical Trial
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving clinical trial approval from the Therapeutic Goods Administration (TGA) of Australia for its 9MW3811, an in-house developed IL-11 monoclonal antibody (mAb) for the treatment of various advanced malignant tumors and fibrotic diseases. This approval marks a significant step forward…
-
AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval
•
UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at the Hainan branch of Shanghai’s Ruijin Hospital this week. The drug is being made available ahead of official approval via the Hainan Bo’ao Lecheng medical pilot zone, offering patients early access to this innovative treatment.…
-
CARsgen Therapeutics Partners with Jinshan Hospital for CAR-T Research
•
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a strategic partnership with Jinshan Hospital of Fudan University, according to a press release. The collaboration aims to advance clinical research and related product development in the field of CAR-T cell therapy. Focus on CAR-T…
-
Sansure Biotech Partners with Shanghai Tenth People’s Hospital for Genomics Center
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai Tenth People’s Hospital to establish a precision genomics testing center. This collaboration aims to enhance the capabilities of both institutions in the field of genomics and molecular diagnostics. Precision Genomics Testing CenterSpecifically, the two parties…
-
Zhongchao and Johnson & Johnson Renew Partnership for Digital Health Services
•
Introduction Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced a renewed agreement with US major Johnson & Johnson (J&J, NYSE: JNJ). This partnership, initially established in 2017 and renewed in 2020, is expected to further enhance cooperation in the innovative healthcare field. Specifically, Zhongchao will provide…
-
CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
•
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted a marketing authorization application (MAA) submitted by its US-based partner EQRx for sugemalimab, a programmed death-1 (PD-1) inhibitor. The application is for the use of sugemalimab in combination with chemotherapy as a first-line treatment for…
-
Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development
•
Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Sequoia Capital China and Sherpa Healthcare Partners, with proceeds intended to accelerate the company’s drug research and development (R&D),…
-
CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs
•
The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent (dupilumab), Sino-US biotech LianBio’s mavacamten, and Anhui Wotai Bio-pharmaceutical Co., Ltd’s sodium benzoate and sodium phenylacetate are on course to obtain priority review statuses. This development highlights the potential of these drugs to address significant…
